At the same time, the pharmaceutical industry is under unprecedented pressure. R&D costs for a single drug can exceed $2 billion, and timelines often stretch over a decade. The global market for AI in pharma is set to surge from $1.2 billion in 2022 to nearly $27 billion by 2027, growing at a staggering 52.7% CAGR.

AI is no longer a “nice-to-have” — it’s becoming the industry’s competitive edge.
The potential impact is dramatic. AI can cut drug discovery timelines by up to 50% and reduce clinical trial costs by as much as 70%. In regulatory affairs, AI tools can shorten approval cycles by up to 40%, saving millions in penalties and accelerating market entry. The problem is, most existing AI models aren’t built for pharma’s unique regulatory complexity. That’s where Vera comes in.
Vera — short for Vertical Regulatory Assistant — is a specialized AI chatbot trained on regulatory data from every major global authority: FDA, EMA, WHO, ICH, CDSCO, MHRA, TGA, and more. Ask Vera to compare EMA Annex 1 with FDA aseptic processing guidelines, and it delivers an instant, clause-level, source-cited answer. 

It understands the language, structure, and nuances of pharma regulations — and it doesn’t just stop at compliance. Vera assists across the full pharmaceutical lifecycle, from ideation and market research to decision-making for product launches